SCHEMBL4876974

SCHEMBL4876974

Cc1cc(C(F)(F)F)c(C#N)c(SCCN2CCN(C3=COC(C4=CC=CCC4)=CO3)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.42
MEN1 O00255 8/20 0.42
BRCA1 P38398 1/20 0.42
ALDH1A1 P00352 6/20 0.41
LMNA P02545 3/20 0.41
PSMD14 O00487 1/20 0.41
HPGD P15428 6/20 0.40
NPSR1 Q6W5P4 4/20 0.40
HTT P42858 2/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 5/20 0.36
L3MBTL1 Q9Y468 4/20 0.35
GAA P10253 4/20 0.34
GLA P06280 2/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4873844 0.85 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1LMNAPSMD14
SCHEMBL4874738 0.85 MEN1 (0.46) KMT2AMEN1ALDH1A1HPGDNPSR1
SCHEMBL4877428 0.84 TP53 (0.36) KMT2AMEN1ALDH1A1LMNAPSMD14
SCHEMBL4873737 0.81 HSD17B10 (0.33) LMNAHSD17B10
SCHEMBL4878115 0.79 TP53 (0.33) TSHRTP53HSD17B10
SCHEMBL4876518 0.79 MEN1 (0.37) KMT2AMEN1ALDH1A1LMNAPSMD14
SCHEMBL6178480 0.79 MEN1 (0.39) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL4876730 0.78 ALDH1A1 (0.37) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL4876267 0.77
SCHEMBL4878132 0.77 ALDH1A1 (0.34) KMT2AMEN1ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393845-B2 Heteroaryl derivates, their preparation and use H. LUNDBECK A/S (DK) 2008-07-01 US claimed
US-20080027071-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2008-01-31 US claimed
EP-1399438-B1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE LUNDBECK & CO AS H (DK) 2005-12-07 EP claimed
US-20040248883-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2004-12-09 US claimed
EP-1399438-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. Lundbeck A/S (DK) 2004-03-24 EP claimed
WO-2003002556-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2003-01-09 WO claimed
US-7393845-B2 Heteroaryl derivates, their preparation and use H. LUNDBECK A/S (DK) 2008-07-01 US disclosed
US-20080027071-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2008-01-31 US disclosed
EP-1399438-B1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE LUNDBECK & CO AS H (DK) 2005-12-07 EP disclosed
US-20040248883-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2004-12-09 US disclosed
EP-1399438-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. Lundbeck A/S (DK) 2004-03-24 EP disclosed
WO-2003002556-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248883-A1 Novel heteroaryl derivatives, their preparation and use GRIN2C, GRIN2B, HTR1A KMT2A 2062/4885MEN1 2129/4885BRCA1 1612/4885
US-20080027071-A1 Novel heteroaryl derivatives, their preparation and use GRIN2C, GRIN2B, HTR2C KMT2A 1897/4885MEN1 2778/4885BRCA1 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.